Caplen; Mary Ann

Patent Applications and Registrations

Patent applications and USPTO patent grants for Caplen; Mary Ann.The latest application filed is for "compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease".

Company Profile

2.10.13

Caplen; Mary Ann - Sayreville NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease Grant 10,414,775 - Caldwell , et al. Sept	2019-09-17
Compounds Useful For Altering The Levels Of Bile Acids For The Treatment Of Diabetes And Cardiometabolc Disease App 20190218224 - Caldwell; John P. ; et al.	2019-07-18
Inhibitors of diacylglycerol acyltransferase Grant 8,716,312 - Ting , et al. May 6, 2	2014-05-06
N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 Grant 8,623,857 - Tsui , et al. January 7, 2	2014-01-07
N-phenyl Imidazole Carboxamide Inhibitors Of 3-phosphoinositide-dependent Protein Kinase-1 App 20130079326 - Tsui; Hon-Chung ; et al.	2013-03-28
Benzenesulfonyl-chromane, Thiochromane, Tetrahydronaphthalene And Related Gamma Secretase Inhibitors App 20120264736 - Asberom; Theodros ; et al.	2012-10-18
Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors Grant 8,067,621 - Asberom , et al. November 29, 2	2011-11-29
Inhibitors Of Diacylglycerol Acyltransferase App 20110224193 - Ting; Pauline C. ; et al.	2011-09-15
Inhibitors Of Diacylglycerol Acyltransferase App 20110224137 - Ting; Pauline C. ; et al.	2011-09-15
Inhibitors Of Diacylglycerol Acyltransferase App 20110224136 - Ting; Pauline C. ; et al.	2011-09-15
2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders Grant 7,511,146 - Burnett , et al. March 31, 2	2009-03-31
Substituted n-aryl amidines as selective D.sub.1 dopamine receptor antagonists for the treatment of obesity and CNS disorders Grant 7,423,149 - Burnett , et al. September 9, 2	2008-09-09
Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors App 20070197581 - Asberom; Theodros ; et al.	2007-08-23
2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders Grant 7,214,691 - Wu , et al. May 8, 2	2007-05-08
Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders App 20050137210 - Burnett, Duane A. ; et al.	2005-06-23
Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1 Grant 6,903,123 - Burnett , et al. June 7, 2	2005-06-07
2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders App 20050054628 - Burnett, Duane A. ; et al.	2005-03-10
2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders App 20050049269 - Wu, Wen-Lian ; et al.	2005-03-03
Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1 App 20040157822 - Burnett, Duane A. ; et al.	2004-08-12
Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1 App 20030195185 - Burnett, Duane A. ; et al.	2003-10-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.